Why is Pfizer falling/rising?

As of 16-Jul, Pfizer Ltd. is experiencing a decline in its stock price, currently at 5,362.85, reflecting a decrease of 76.15 points or 1.4%. The stock has underperformed its sector today by 1.13%, and its delivery volume has significantly dropped by 49.88% compared to the 5-day average, indicating falling investor participation. Over the past week, the stock has decreased by 5.48%, while it has shown a more modest year-to-date increase of 2.07%. Despite having a high management efficiency with a return on equity of 19.67% and a low debt-to-equity ratio, the stock's recent performance has been hindered by its underperformance relative to the benchmark, as it has fallen more sharply than the Sensex, which is down only 1.08% over the same period.
In the broader market context, Pfizer's short-term performance is notably weaker than the benchmark, as it has declined more than the Sensex in the past week. The stock's current liquidity suggests it is still viable for trading, but the high dividend yield of 3.68% may not be enough to offset the negative sentiment reflected in its recent price movements. Overall, while the company has shown strong financial metrics, including record net sales and operating profit margins, the current market conditions and investor behavior are contributing to the stock's downward trend.